CA2624957A1 - Therapeutic peptides and vaccines - Google Patents

Therapeutic peptides and vaccines Download PDF

Info

Publication number
CA2624957A1
CA2624957A1 CA002624957A CA2624957A CA2624957A1 CA 2624957 A1 CA2624957 A1 CA 2624957A1 CA 002624957 A CA002624957 A CA 002624957A CA 2624957 A CA2624957 A CA 2624957A CA 2624957 A1 CA2624957 A1 CA 2624957A1
Authority
CA
Canada
Prior art keywords
peptide
composition
group
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002624957A
Other languages
English (en)
French (fr)
Inventor
Candace Pert
Michael Ruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAPID Pharmaceuticals AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2624957A1 publication Critical patent/CA2624957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA002624957A 2005-06-23 2006-06-23 Therapeutic peptides and vaccines Abandoned CA2624957A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US69308805P 2005-06-23 2005-06-23
US69308905P 2005-06-23 2005-06-23
US69308705P 2005-06-23 2005-06-23
US60/693,088 2005-06-23
US60/693,089 2005-06-23
US60/693,087 2005-06-23
PCT/US2006/024580 WO2006138745A2 (en) 2005-06-23 2006-06-23 Therapeutic peptides and vaccines

Publications (1)

Publication Number Publication Date
CA2624957A1 true CA2624957A1 (en) 2006-12-28

Family

ID=37571305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002624957A Abandoned CA2624957A1 (en) 2005-06-23 2006-06-23 Therapeutic peptides and vaccines

Country Status (9)

Country Link
US (3) US7700115B2 (https=)
EP (1) EP1893233A4 (https=)
JP (1) JP2008546803A (https=)
KR (1) KR20080019720A (https=)
AU (1) AU2006261133B2 (https=)
BR (1) BRPI0611927A2 (https=)
CA (1) CA2624957A1 (https=)
MX (1) MX2007016573A (https=)
WO (1) WO2006138745A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
US8178497B2 (en) 2007-11-14 2012-05-15 Rapid Pharmaceuticals Ag Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
US20210244788A1 (en) * 2020-02-06 2021-08-12 Creative Bio-Peptides Inc. Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
JP2680011B2 (ja) * 1986-06-03 1997-11-19 アメリカ合衆国 Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類
US5276016A (en) * 1986-06-03 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
US6011014A (en) 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5534495A (en) 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US20040126811A1 (en) * 2002-02-21 2004-07-01 Thomas Boren Helicobacter pylori sialic acid binding adhesin, saba and saba-gene
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines

Also Published As

Publication number Publication date
US20100184705A1 (en) 2010-07-22
EP1893233A2 (en) 2008-03-05
JP2008546803A (ja) 2008-12-25
EP1893233A4 (en) 2010-03-31
US10973906B2 (en) 2021-04-13
AU2006261133A1 (en) 2006-12-28
AU2006261133B2 (en) 2012-04-05
KR20080019720A (ko) 2008-03-04
BRPI0611927A2 (pt) 2011-08-16
US10071153B2 (en) 2018-09-11
MX2007016573A (es) 2008-10-17
US7700115B2 (en) 2010-04-20
US20060292167A1 (en) 2006-12-28
WO2006138745A2 (en) 2006-12-28
US20190000964A1 (en) 2019-01-03
WO2006138745A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US10973906B2 (en) Therapeutic peptides and vaccines
Root et al. HIV-1 gp41 as a target for viral entry inhibition
Koch et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition
Xiang et al. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies
Naidu et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac
Yuan et al. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker
US8173767B2 (en) Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
Srivastava et al. Role of neutralizing antibodies in protective immunity against HIV
JP2004522401A (ja) ワクチンおよび治療薬としてのｃｄ４非依存性のｈｉｖエンベロープタンパク質
CA2305341C (en) Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
Lagenaur et al. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates
Shibata et al. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate
DeVico CD4-induced epitopes in the HIV envelope glycoprotein, gp120
WO1998000535A2 (en) Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
Lin et al. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein
CA2267662A1 (en) Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
WO1998015569A9 (en) Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
Steimer et al. HIV-1 neutralization directed to epitopes other than linear V3 determinants
CN101242854A (zh) 治疗肽及疫苗
US7524927B2 (en) Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
Matsumi et al. Neutralizing monoclonal antibody against an external envelope glycoprotein (gp110) of SIVmac251
Sanders The HIV-1 Envelope Glycoproteins: Folding, Function and Vaccin Design
Fellinger Interactions Between Primate Immunodeficiency Virus Envelope Glycoproteins and Their Receptors
Guenaga Epitope Scaffolds And The HIV-1 gp41 2F5 Neutralization Determinant
Srivastava et al. Challenges in Designing HIV Env Immunogens for Developing a Vaccine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140822